Business Context and Reporting Period
Company: Alector, Inc. (ALEC)
Filing Type: Form 8-K (Current Report)
Report Date: February 25, 2026
Reporting Period: Quarter ended December 31, 2025
Business Context: The filing announces the financial results for the fourth quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the financial results but does not contain the specific numerical data within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific values for revenue, profit, cash flow, and liquidity are located in the attached Exhibit 99.1 (Press Release) and are not present in the filing text provided.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. It only confirms the announcement of results for the quarter ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management has released a press release (Exhibit 99.1) containing the results, but the text of the commentary is not included in this document.
Guidance and Outlook: No forward-looking guidance or outlook is provided in the text of this filing.
Risks and Contingencies: No specific risks or contingencies are detailed in this text. The filing includes a standard disclaimer that the information in Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 25, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" referenced in Item 2.02, as they are not embedded in the 8-K text.
- Check for any updated clinical trial milestones or partnership announcements typically included in the accompanying press release.
- Confirm the company's cash runway and burn rate, which are critical for a biotechnology firm and are absent from this summary text.